Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Dow
Merck
AstraZeneca
Boehringer Ingelheim

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR TALAZOPARIB TOSYLATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Talazoparib Tosylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02282345 ↗ Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer Active, not recruiting Medivation, Inc. Phase 2 2015-04-16 This phase II trial studies the side effects of talazoparib when given before standard therapy in treating patients with breast cancer that has spread to nearby healthy tissue and has a mutation in a breast cancer, early onset (BRCA) gene. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may be especially effective in patients with BRCA mutations. It is not yet known whether adding talazoparib before standard treatment is safe in treating patients with BRCA mutated breast cancer.
NCT02282345 ↗ Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer Active, not recruiting National Cancer Institute (NCI) Phase 2 2015-04-16 This phase II trial studies the side effects of talazoparib when given before standard therapy in treating patients with breast cancer that has spread to nearby healthy tissue and has a mutation in a breast cancer, early onset (BRCA) gene. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may be especially effective in patients with BRCA mutations. It is not yet known whether adding talazoparib before standard treatment is safe in treating patients with BRCA mutated breast cancer.
NCT02282345 ↗ Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer Active, not recruiting M.D. Anderson Cancer Center Phase 2 2015-04-16 This phase II trial studies the side effects of talazoparib when given before standard therapy in treating patients with breast cancer that has spread to nearby healthy tissue and has a mutation in a breast cancer, early onset (BRCA) gene. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may be especially effective in patients with BRCA mutations. It is not yet known whether adding talazoparib before standard treatment is safe in treating patients with BRCA mutated breast cancer.
NCT02286687 ↗ Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes Recruiting BioMarin Pharmaceutical Phase 2 2014-12-22 This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes. Talazoparib may cause tumor cells to die by blocking an enzyme that protects the tumor cells from damage.
NCT02286687 ↗ Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes Recruiting National Cancer Institute (NCI) Phase 2 2014-12-22 This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes. Talazoparib may cause tumor cells to die by blocking an enzyme that protects the tumor cells from damage.
NCT02286687 ↗ Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes Recruiting M.D. Anderson Cancer Center Phase 2 2014-12-22 This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes. Talazoparib may cause tumor cells to die by blocking an enzyme that protects the tumor cells from damage.
NCT02316834 ↗ Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting BioMarin Pharmaceutical Early Phase 1 2015-06-02 This pilot early phase I trial studies talazoparib to determine if certain characteristics of the deoxyribonucleic acid (DNA) affect how the disease responds to therapy in patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Studying samples of tissue in the laboratory from patients receiving talazoparib may help doctors learn more about the effects of talazoparib on cells and may help doctors understand how well patients respond to treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Talazoparib Tosylate

Condition Name

Condition Name for Talazoparib Tosylate
Intervention Trials
Advanced Breast Cancer 2
Advanced Malignant Solid Neoplasm 2
HER2/Neu Negative 2
Breast Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Talazoparib Tosylate
Intervention Trials
Breast Neoplasms 3
Adenocarcinoma 2
Neoplasms 2
Lung Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Talazoparib Tosylate

Trials by Country

Trials by Country for Talazoparib Tosylate
Location Trials
United States 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Talazoparib Tosylate
Location Trials
Texas 5
New York 3
California 3
Virginia 1
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Talazoparib Tosylate

Clinical Trial Phase

Clinical Trial Phase for Talazoparib Tosylate
Clinical Trial Phase Trials
Phase 2 5
Phase 1/Phase 2 1
Phase 1 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Talazoparib Tosylate
Clinical Trial Phase Trials
Recruiting 5
Active, not recruiting 3
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Talazoparib Tosylate

Sponsor Name

Sponsor Name for Talazoparib Tosylate
Sponsor Trials
National Cancer Institute (NCI) 7
M.D. Anderson Cancer Center 4
Pfizer 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Talazoparib Tosylate
Sponsor Trials
Other 9
Industry 8
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Merck
Harvard Business School
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.